NCT01278082已完成3 期
Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules Versus Placebo for Maintenance of Remission in Patients With Collagenous Colitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 92
- 试验地点
- 2
- 主要终点
- Proportion of patients being in remission over 52 weeks.
研究概览
简要总结
This study aims to demonstrate the superiority of budesonide compared to placebo as maintenance therapy in keeping patients in remission over a one-year period
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent,
- •Patients aged >= 18 years,
- •Histologically established diagnosis of collagenous colitis (CC) defined as:
- •Thickened sub-epithelial collagen layer >= 10 µm on well-orientated sections,
- •Increased amount of inflammatory cells indicating chronic inflammation in the lamina propria,
- •History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in patients with newly diagnosed collagenous colitis, or history of clinical relapse for more than 1 week prior screening in patients with previously established collagenous colitis,
- •A mean of >= 3 stools/day, thereof a mean of >= 1 watery stools/day, during the week prior baseline,
- •Women of child-bearing potential and being heterosexually active have to apply appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation.
排除标准
- •Other significant abnormalities at colonoscopy that may have been the cause of diarrhoea, with the exception of colonic diverticulosis and polyps < 2 cm,
- •Infectious cause of diarrhoea,
- •Untreated active celiac disease,
- •Clinical suspicion of drug-induced collagenous colitis,
- •Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,
- •Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension,
- •Local intestinal infection,
- •Radiation therapy towards the abdominal or pelvic region,
- •Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease, or hypertension if careful medical monitoring is not ensured,
- •Known established cataract,
- •Known hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency, Lapp lactase deficiency, or congenital lactase deficiency,
- •Established osteoporosis with T-score < -2.5,
- •Pregnancy or lactation,
- •History of cancer in the last five years,
- •History of significant bowel resection,
- •Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) in the last 3 months,
- •Treatment with oral, rectal, or intravenous corticosteroids including budesonide in the last month,
- •Known intolerance/hypersensitivity to study drug or drugs of similar chemical structure or pharmacological profile,
- •Patients who are unable to adhere to the study visit schedule and other protocol requirements according to the judgement of the investigator,
- •Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
研究组 & 干预措施
A
Experimental
Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
干预措施: Budesonide (Drug)
B
Placebo Comparator
Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of patients being in remission over 52 weeks.
时间窗: 52 weeks
Remission is defined as a mean of \< 3 stools/day, thereof a mean of \< 1 watery stools/day
次要结局
- Adverse events (AEs)(52 weeks)
- Proportion of patients in remission at wk 4, 13, 26, and 39.(39 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic EsophagitisEosinophilic EsophagitisNCT02434029Dr. Falk Pharma GmbH88
已完成
3 期
Budesonide for Induction of Remission in Incomplete Microscopic ColitisIncomplete Microscopic ColitisNCT02142634Dr. Falk Pharma GmbH44
已完成
3 期
Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic EsophagitisEosinophilic EsophagitisNCT02493335Dr. Falk Pharma GmbH204
已完成
2 期
Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of ARSeasonal Allergic RhinitisNCT00938613Ligand Pharmaceuticals65
已完成
2 期
Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative ProctitisProctitisNCT01966783Dr. Falk Pharma GmbH320